Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

NCT01243346 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

D842-related Mutant GIST

Interventions

DRUG: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

Sponsor

Arog Pharmaceuticals, Inc.